April 4: The Week in Cancer News
Some early-stage breast cancer patients may not need surgery, and FDA approves Imfinzi for muscle-invasive bladder cancer.
Progress Against Cancer
Some early-stage breast cancer patients may not need surgery, and FDA approves Imfinzi for muscle-invasive bladder cancer.
Saliva test can help identify people who are at high risk of recurrence after mouth or throat cancer treatment.
Researchers analyze whether giving immunotherapy before surgery benefits people with high-risk disease that is limited to the liver.
Patients who received Opdivo and chemotherapy had better outcomes and fewer side effects than those who had the standard-of-care therapy.
An experimental antibody helped people recover body mass lost due to cancer and treatment.
Shorter, more intense radiation regimens may be as effective as traditional treatments, with greater convenience for patients.
People with metastatic hormone receptor-positive breast cancer are living longer, thanks to new targeted therapies and endocrine therapies that can be prescribed when treatment resistance develops.
Blood tests can guide treatment choices, delivering results in less time than traditional biopsies.
New prostate cancer surgery approach can prevent sexual side effects, and some people with esophageal cancer may be able to avoid surgery.
This month, the editors of AACR's journals tout studies showcasing the immunostimulatory impact of senescent cancer cells, a novel bispecific immunotherapy, and more.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now